News

UK and US Strike Ground-Breaking Zero-Tariff Pharma Deal

This shift is expected to accelerate patient access to advanced therapies, including breakthrough cancer drugs and medicines for rare diseases that previously struggled to gain approval due to cost-effectiveness hurdles.

• By Newsdesk
• New Delhi
• Dec 02, 2025

News

The United Kingdom and the United States have finalised a landmark agreement that removes all tariffs on UK pharmaceutical exports for the next three years, marking one of the most significant trade developments between the two countries in recent years. The deal eliminates import duties on UK-made medicines, ingredients, and medical technologies, giving British manufacturers the most favourable tariff terms currently offered by the US.

As part of the agreement, the UK has committed to increasing the National Health Service’s spending on new and effective treatments, the first major rise in such allocations in more than two decades. This shift is expected to accelerate patient access to advanced therapies, including breakthrough cancer drugs and medicines for rare diseases that previously struggled to gain approval due to cost-effectiveness hurdles.

Industry bodies have welcomed the pact, saying it strengthens the UK’s position as an attractive hub for life-sciences investment. Pharmaceutical companies anticipate smoother market access, greater predictability, and renewed confidence in both countries' regulatory collaboration.

US officials, meanwhile, described the accord as a step towards correcting long-standing imbalances in bilateral pharmaceutical trade. The wider trade package also features tariff reductions across several industries, including automobiles, steel, and medical technologies.

For the UK, the zero-tariff agreement represents both an economic opportunity and a healthcare milestone, promising expanded export potential while enabling faster availability of innovative treatments for patients at home.